202 related articles for article (PubMed ID: 24011542)
21. Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP/PS1 mouse model of Alzheimer's disease.
Filali M; Lalonde R; Rivest S
Neuropharmacology; 2011 May; 60(6):930-6. PubMed ID: 21281652
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy of memantine in the treatment of Alzheimer's disease].
Molinuevo Guix JL; Lladó Plarrumaní A
Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
[TBL] [Abstract][Full Text] [Related]
23. In vitro galantamine-memantine co-application: mechanism of beneficial action.
Zhao X; Marszalec W; Toth PT; Huang J; Yeh JZ; Narahashi T
Neuropharmacology; 2006 Dec; 51(7-8):1181-91. PubMed ID: 17011596
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol.
Culmsee C; Junker V; Kremers W; Thal S; Plesnila N; Krieglstein J
Stroke; 2004 May; 35(5):1197-202. PubMed ID: 15060319
[TBL] [Abstract][Full Text] [Related]
25. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
Wenk GL
J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
[TBL] [Abstract][Full Text] [Related]
26. Memantine: pharmacological properties and clinical uses.
Kumar S
Neurol India; 2004 Sep; 52(3):307-9. PubMed ID: 15472417
[TBL] [Abstract][Full Text] [Related]
27. [Memantine].
Molinuevo JL
Neurologia; 2003 Jun; 18(5):255-61. PubMed ID: 12768511
[TBL] [Abstract][Full Text] [Related]
28. Dose-dependent folic acid and memantine treatments promote synergistic or additive protection against Aβ(25-35) peptide-induced apoptosis in SH-SY5Y cells mediated by mitochondria stress-associated death signals.
Chen TF; Tang MC; Chou CH; Chiu MJ; Huang RF
Food Chem Toxicol; 2013 Dec; 62():538-47. PubMed ID: 24055771
[TBL] [Abstract][Full Text] [Related]
29. Comparison of donepezil and memantine for protective effect against amyloid-beta(1-42) toxicity in rat septal neurons.
Kimura M; Komatsu H; Ogura H; Sawada K
Neurosci Lett; 2005 Dec; 391(1-2):17-21. PubMed ID: 16154269
[TBL] [Abstract][Full Text] [Related]
30. Cognitive dysfunction induced by sequential injection of amyloid-beta and ibotenate into the bilateral hippocampus; protection by memantine and MK-801.
Nakamura S; Murayama N; Noshita T; Katsuragi R; Ohno T
Eur J Pharmacol; 2006 Oct; 548(1-3):115-22. PubMed ID: 16952349
[TBL] [Abstract][Full Text] [Related]
31. Therapies for Alzheimer's disease.
Melnikova I
Nat Rev Drug Discov; 2007 May; 6(5):341-2. PubMed ID: 17539055
[No Abstract] [Full Text] [Related]
32. Mechanism of action of memantine.
Johnson JW; Kotermanski SE
Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
[TBL] [Abstract][Full Text] [Related]
33. Cognitive changes under memantine according to vitamin D status in Alzheimer patients: An exposed/unexposed cohort pilot study.
Lemire P; Brangier A; Beaudenon M; Duval GT; Annweiler C
J Steroid Biochem Mol Biol; 2018 Jan; 175():151-156. PubMed ID: 28042052
[TBL] [Abstract][Full Text] [Related]
34. Possible synergistic effect of direct angiotensin II type 2 receptor stimulation by compound 21 with memantine on prevention of cognitive decline in type 2 diabetic mice.
Iwanami J; Mogi M; Tsukuda K; Jing F; Ohshima K; Wang XL; Nakaoka H; Kan-no H; Chisaka T; Bai HY; Min LJ; Horiuchi M
Eur J Pharmacol; 2014 Feb; 724():9-15. PubMed ID: 24361310
[TBL] [Abstract][Full Text] [Related]
35. Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer's disease.
Sozio P; Cerasa LS; Laserra S; Cacciatore I; Cornacchia C; Di Filippo ES; Fulle S; Fontana A; Di Crescenzo A; Grilli M; Marchi M; Di Stefano A
Eur J Pharm Sci; 2013 May; 49(2):187-98. PubMed ID: 23454012
[TBL] [Abstract][Full Text] [Related]
36. Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments.
Maurice T
Behav Brain Res; 2016 Jan; 296():270-278. PubMed ID: 26386305
[TBL] [Abstract][Full Text] [Related]
37. Memantine in moderate-to-severe Alzheimer's disease.
Reisberg B; Doody R; Stöffler A; Schmitt F; Ferris S; Möbius HJ;
N Engl J Med; 2003 Apr; 348(14):1333-41. PubMed ID: 12672860
[TBL] [Abstract][Full Text] [Related]
38. Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets.
Zádori D; Veres G; Szalárdy L; Klivényi P; Toldi J; Vécsei L
J Alzheimers Dis; 2014; 42 Suppl 3():S177-87. PubMed ID: 24670398
[TBL] [Abstract][Full Text] [Related]
39. Neuroprotective effects of combined therapy with memantine, donepezil, and vitamin D in ovariectomized female mice subjected to dementia model.
Vieira ADC; Medeiros EB; Zabot GC; Pereira NS; do Nascimento NB; Lidio AV; Scheffer ÂK; Rempel LCT; Macarini BMN; Costa MA; Gonçalves CL; Kucharska E; Rodrigues MS; Moreira JCF; de Oliveira J; Budni J
Prog Neuropsychopharmacol Biol Psychiatry; 2023 Mar; 122():110653. PubMed ID: 36195205
[TBL] [Abstract][Full Text] [Related]
40. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias.
Molinuevo JL; Lladó A; Rami L
Am J Alzheimers Dis Other Demen; 2005; 20(2):77-85. PubMed ID: 15844753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
